CD19-CAR-NK（JD Biotech）

N/A

Report date: 2022/12/12 20:00:45

Base Information

Drug NameCD19-CAR-NK（JD Biotech）
Drug Alias NameJD010JD-010
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing JD Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing JD Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A